Alisporivir

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Alisporivir
Alisporivir.svg
Clinical data
Legal status
?
Identifiers
CAS number 254435-95-5 YesY
ATC code None
PubChem CID 11513676
ChemSpider 9688467 YesY
KEGG D10087 N
ChEMBL CHEMBL1651956 N
NIAID ChemDB 268533
Chemical data
Formula C63H113N11O12 
Mol. mass 1216.64 g/mol
 N (what is this?)  (verify)

Alisporivir (INN), or Debio 025, DEB025, (or UNIL-025) is a cyclophilin inhibitor.[1] Its structure is reminiscent of, and synthesized from ciclosporin.

It inhibits cyclophilin A.[2] Alisporivir is not immunosuppressive.[3]

It is being researched for potential use in the treatment of hepatitis C.[4][5] It has also been investigated for Duchenne muscular dystrophy.[1]

Alisporivir is under development by Debiopharm for Japan and by Novartis for the rest of the world (licence granted by Debiopharm) since February 2010.

References[edit]

  1. ^ a b Reutenauer J, Dorchies OM, Patthey-Vuadens O, Vuagniaux G, Ruegg UT (October 2008). "Investigation of Debio 025, a cyclophilin inhibitor, in the dystrophic mdx mouse, a model for Duchenne muscular dystrophy". Br. J. Pharmacol. 155 (4): 574–84. doi:10.1038/bjp.2008.285. PMC 2579666. PMID 18641676. 
  2. ^ Gallay, PA; Lin K. (15 February 2013). "Profile of alisporivir and its potential in the treatment of hepatitis C.". Drug Des Devel Ther. 7: 105–115. doi:10.2147/DDDT.S30946. PMID 23440335. 
  3. ^ Ptak RG, Gallay PA, Jochmans D, et al. (April 2008). "Inhibition of human immunodeficiency virus type 1 replication in human cells by Debio-025, a novel cyclophilin binding agent". Antimicrob. Agents Chemother. 52 (4): 1302–17. doi:10.1128/AAC.01324-07. PMC 2292519. PMID 18212100. 
  4. ^ Paeshuyse J, Kaul A, De Clercq E, et al. (April 2006). "The non-immunosuppressive cyclosporin DEBIO-025 is a potent inhibitor of hepatitis C virus replication in vitro". Hepatology 43 (4): 761–70. doi:10.1002/hep.21102. PMID 16557546. 
  5. ^ Coelmont L, Kaptein S, Paeshuyse J, et al. (December 2008). "Debio 025, a cyclophilin binding molecule, is highly efficient in clearing HCV replicon containing cells, alone or when combined with Specifically Targeted Antiviral Therapy for HCV (STAT-C) inhibitors". Antimicrob. Agents Chemother. 53 (3): 967–76. doi:10.1128/AAC.00939-08. PMC 2650540. PMID 19104013.